Clinical Assoc. Prof. in Department of Clinical Oncology
Dr Herbert H. Loong holds conjoint appointments of Clinical Associate Professor in the Department of Clinical Oncology and Deputy Medical Director of the Phase 1 Clinical Trials Centre of The Chinese University of Hong Kong.
Dr Loong obtained his medical degree with a Distinction in Surgery from The University of Hong Kong in 2003. He has completed a Fellowship in Drug Development at Princess Margaret Cancer Centre in Toronto, Canada with a focus on Experimental Therapeutics. His clinical and research interests include Thoracic Oncology, Sarcoma Medical Oncology and Health Economics.
Dr Loong is a recipient of the European Cancer Congress Fellowship Grant (2013), the American Society of Clinical Oncology (ASCO) Annual Meeting Merit Award (2014), the Hong Kong College of Physicians Young Investigators’ Award (2014). Dr. Loong led the Lung Cancer Team at CUHK to be bestowed the IASLC Foundation Cancer Care Team Award in recognition for providing the best thoracic oncology care in “Asia & Rest of the World” in 2018.
In recent years, Dr Loong has co-founded the Asia Pacific Oncology Drug Development Consortium (APODDC) and the Asia Pacific Coalition Against Lung Cancer (APCLC).
Dr Loong has served or continues to serve in various capacities in various professional international oncology bodies, including the International Affairs Committee and the Asia-Pacific Regional Council of ASCO, the Membership, Education and Communications Committees of the IASLC. He is the incoming Chairman of the International Affairs Committee of ASCO in 2024. He has been elected as a Board Member of the Connective Tissue Oncology Society (CTOS) for 2022-2024. In his prior appointment as a member of Pharmacy and Poisons Board of Hong Kong, he oversaw the registration of medicinal products and clinical trials in the territory.
AbbVie, Amgen, Bayer, Boehringer-Ingelheim, Celgene, Eisai, Eli-Lilly, George Clinical, Guardant Health, Illumina, Janssen, Novartis, Merck Sereno, Pfizer, Takeda
Molecular testing challenges and optimal biomarker testing approaches in lung and prostate cancer